MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (” MyMD” or “the Company”), a clinical phase pharmaceutical firm committed to extending healthy and balanced life expectancy, today announced that the initial client has actually been enrolled in the Business’s Phase 2 scientific test of lead candidate MYMD-1, an oral immune regulator drug, as a treatment for postponing aging and broadening healthy and balanced life expectancy.
The main endpoint for the Stage 2 double-blind, placebo-controlled clinical test is to attain a decrease in the circulating levels of (TNF-α), tumor necrosis element receptor I (TNFRI) and also IL-6. TNF-α and IL-6 are the proteins in the body that create inflammation and aid trigger the procedure of aging. The secondary measures of the test will certainly be the security, tolerability, as well as pharmacokinetics in this population of individuals.
” In a Stage 1 professional trial of MYMD-1, we demonstrated the medication’s statistically significant effectiveness in reducing degrees of TNF-α, a key player in causing pathological aging, in the blood. The FDA has actually accepted TNF-α reduction as the key endpoint for our Stage 2 research, which our company believe settings us well for a successful Phase 2 outcome,” stated Chris Chapman, M.D., Head Of State, Supervisor and also Chief Medical Officer of MyMD. “The initiation of patient registration in this research advances our objective to slow the aging process, protect against loss of muscle tissue in aging, restriction frailty, and also extend healthy and balanced life expectancy.”
MyMD has actually mentioned that there are no FDA-approved drugs for dealing with aging conditions as well as prolonging healthy life expectancy human beings, a market expected to be at the very least $600 billion by 20251 according to a significant financial investment financial institution. TNF-α blockers are the most proposed medications by profits, a worldwide market of roughly $40 billion per year,2 and also, according to Nature Aging journal,3 a slowdown in maturing that would certainly raise life expectancy by one year deserves $38 trillion and by 10 years is worth $367 trillion.
In addition to aging, MYMD-1’s distinctive activity in controling the body immune system as well as dealing with chronic inflammation is being developed for the treatment of autoimmune disease, consisting of rheumatoid arthritis (RA), several sclerosis (MS), diabetic issues, as well as inflammatory bowel disease.
” We intend to begin writing protocols for a Phase 2 pilot research study of MYMD-1 for rheumatoid joint inflammation early this year,” Dr. Chapman noted. “The increasing occurrence of rheumatoid joint inflammation and also other autoimmune and also inflammatory diseases are driving need for TNF preventions like MYMD-1, as well as we believe our by mouth carried out medicine with really reduced poisoning would certainly be turbulent to the $60 billion market for RA if accepted by the FDA for this indicator.”
Rheumatoid joint inflammation affects about 40 million individuals around the world.4.
Originally established for autoimmune conditions, MYMD-1’s primary function is to reduce the aging process, prevent sarcopenia and frailty, and also prolong healthy lifespan. Since it can go across the blood-brain barrier as well as access to the main nerve system (CNS), MYMD-1 is additionally positioned to be a feasible treatment for brain-related problems. Its system of activity and efficiency in diseases including numerous sclerosis (MS) as well as thyroiditis have been researched through partnerships with several scholastic organizations. MYMD-1 is also showing promise in pre-clinical studies as a possible therapy for message- COVID-19 issues and also as an anti-fibrotic as well as anti-proliferation restorative.
MYMD-1 has actually shown effectiveness in pre-clinical researches in controling the body immune system by doing as a selective prevention of lump death factor-alpha (TNF-α), a motorist of persistent inflammation. Unlike other treatments, MYMD-1 has actually been displayed in these pre-clinical researches to selectively obstruct TNF-α when it becomes overactivated in autoimmune conditions and also cytokine storms, but not obstruct it from doing its typical work of being an initial -responder to any type of regular kind of modest infection. MYMD-1’s convenience of dental dosing is one more differentiator compared to currently offered TNF-α blockers, every one of which require shipment by shot or mixture. No authorized TNF prevention has actually ever been dosed orally. Additionally, the medication is not immunosuppressive and has actually not been revealed to create the major adverse effects usual with standard therapies that deal with swelling.
Concerning MyMD Pharmaceuticals, Inc
. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical business committed to extending healthy and balanced life-span, is concentrated on developing 2 novel therapeutic platforms that treat the causes of disease rather than only attending to the signs. MYMD-1 is a drug system based upon a scientific stage small molecule that controls the body immune system to manage TNF-α, which drives persistent swelling, and various other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase long life, and deal with autoimmune illness and COVID-19- connected anxiety. The Company’s second medication system, Supera-CBD, is being established to treat persistent pain, addiction as well as epilepsy. Supera-CBD is a novel synthetic by-product of cannabidiol (CBD) and also is being developed to address and improve upon the swiftly growing CBD market, that includes both FDA approved drugs and CBD items not presently regulated as medications. To learn more, go to www.mymd.com.